Literature DB >> 8624693

Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.

G L Defer1, C Geny, F Ricolfi, G Fenelon, J C Monfort, P Remy, G Villafane, R Jeny, Y Samson, Y Keravel, A Gaston, J D Degos, M Peschanski, P Cesaro, J P Nguyen.   

Abstract

Five patients with Parkinson's disease, unilaterally transplanted with foetal mesencephalic cells into putamen (n=1) or putamen and caudate (n=4), were followed throughout a period of 15-36 months after surgery, according to the recommendations of the core assessment programme for intracerebral transplantations (CAPIT). All these patients exhibited an increase in the fluorodopa uptake in the grafted putamen, which was most significant in the first and last patient of the series. Long-term bilateral improvement of skilled hand movements was observed, starting between the third and sixth month after grafting, and confirmed by the statistical analysis of CAPIT timed tests. A mild to moderate effect on the amount of 'off' time and 'on-off' fluctuations was observed, whereas, apart from one case, no other clear effect on gait, walking and speech was found. One patient included in the study, already suffering slight cognitive impairment, clearly exhibited progression of a dementia process after surgery. Daily living activities were clearly improved in only one of the other four patients. At the end of the study period, all patients needed L-dopa therapy at a similar or higher dose than before grafting, but, in most of them, other dopaminergic drugs were reduced or stopped. All patients exhibited bilateral dyskinesias before grafting that were greatly decreased in intensity a few months after surgery. Delayed asymmetrical dyskinesias, occurring on the side displaying the better motor improvement, i.e. contralateral to the graft, were observed in three patients. These results suggest that neural transplants may influence two central mechanisms involved in motor function and the onset of dyskinesias. These effects are likely to occur through complex interactions with the post-synaptic dopaminergic receptors. The occurrence of dyskinesias might simply reflect increased presynaptic storage and release of dopamine. Alternatively, it might, in part, represent some other long-term deleterious effect of the graft. Since PET-scan data indicate that the reinnervation obtained is sub-optimal, it will be of interest to obtain a larger and denser reinnervation of the host striatum and to try, thereafter, to reduce the dose of L-dopa.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624693     DOI: 10.1093/brain/119.1.41

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  27 in total

Review 1.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

2.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

Review 3.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 4.  Cell-based therapies in Parkinson's disease.

Authors:  Paul Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

5.  Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism.

Authors:  Daniella Rylander; Vincenza Bagetta; Valentina Pendolino; Elisa Zianni; Shane Grealish; Fabrizio Gardoni; Monica Di Luca; Paolo Calabresi; M Angela Cenci; Barbara Picconi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

Review 6.  Cell therapeutics in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 7.  Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies.

Authors:  Brigitte Onténiente; Sowmyalakshmí Rasika; Alexandra Benchoua; Christelle Guégan
Journal:  Mol Neurobiol       Date:  2003-02       Impact factor: 5.590

8.  Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges.

Authors:  Camille Nicoleau; Pedro Viegas; Marc Peschanski; Anselme L Perrier
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

9.  Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.

Authors:  D E Redmond; A Vinuela; J H Kordower; O Isacson
Journal:  Neurobiol Dis       Date:  2007-08-28       Impact factor: 5.996

Review 10.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.